In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche brings in RNAi capabilities through Alnylam deal' Arrowhead takes over deal

Executive Summary

Alnylam Pharmaceuticals (develops medicines that turn off disease-causing genes) has granted Roche nonexclusive rights to its RNA interference (RNAi) platform. The Big Pharma is also buying Alnylam's Kulmbach, Germany, R&D site and will convert it into a Center of Excellence focusing on RNAi therapeutics.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies